GlassScriptPhysician profile
Jette Hooper
NPI 1578069530
$2,163.85
in general payments reported to CMS, 2019-2025
20 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $443 · 2023: $1,119 · 2024: $328 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648 · Education: $73.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,647.76 |
| Education | $73.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $687.47 | 2022-2025 | |
| Leo Pharma INC. | $228.96 | 2022-2025 | Adbry, Anzupgo |
| Pfizer INC. | $217.49 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $205.54 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $178.43 | 2022-2023 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $84.20 | 2024-2025 | |
| Galderma Laboratories, L.P. | $76.61 | 2022-2025 | Nemluvio |
| Genzyme Corporation | $73.02 | 2023-2024 | |
| Ucb, INC. | $62.99 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $61.51 | 2023-2024 | Tremfya, Simponi Aria, Remicade |
| Arcutis Biotherapeutics, INC. | $54.69 | 2023 | |
| Kerecis Limited | $46.22 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Dermavant Sciences, INC. | $41.22 | 2023 | Vtama |
| Mimedx Group, INC. | $30.06 | 2025 | |
| Incyte Corporation | $28.17 | 2024 | Opzelura |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.37 | 2024 | Cabtreo |
| Journey Medical Corporation | $19.56 | 2023 | |
| Botanix Sb INC | $17.49 | 2025 | Sofdra |
| Amgen INC. | $13.45 | 2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $13.40 | 2023 | Ilumya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jette Hooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.